Måndag 8 December | 00:09:04 Europe / Stockholm

Kalender

Est. tid*
2025-08-28 - Kvartalsrapport 2025-Q2
2025-04-07 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2025-04-04 - Årsstämma
2025-03-07 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-05 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2024-04-04 - Årsstämma
2024-03-07 - Bokslutskommuniké 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-03-31 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2023-03-30 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-06 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2022-04-05 - Årsstämma
2022-03-02 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorInformationsteknik
IndustriProgramvara
Aiforia Technologies utrustar patologer och forskare i prekliniska och kliniska laboratorier med programvara för att översätta bilder till upptäckter, beslut och diagnoser. Bolagets produkter och tjänster används för medicinsk bildanalys, över en mängd olika områden såsom onkologi samt neurovetenskap. Aiforia Technologies har sitt huvudkontor i Finland.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-10-31 08:00:00

Inside information: Aiforia initiates change negotiations to improve the company's competitiveness and profitability

Aiforia Technologies Plc, Inside information, October 31, 2025 at 09:00 a.m. EET

Aiforia Technologies Plc is initiating change negotiations to enhance the company's business competitiveness and profitability. The financial adjustment measures are intended to ensure the achievement of the company’s mid-term strategic goals.

The planned financial adjustments are expected to deliver ongoing annual cost savings of approximately EUR 2.5 million, starting from the 2026 financial year. The majority of the savings are intended to be covered by other cost savings than personnel expenses. The share of personnel expenses in the adjustment measures is estimated to be approximately 650,000 euros.

The change negotiations concern Aiforia Technologies Plc's operations in Finland. A total of 43 people are within the scope of the negotiations. Based on the company's assessment, the need to reduce personnel is less than 10 people. Aiforia Technologies Plc's operations in Finland employ a total of 62 people.

"We are moving into the next strategic phase of the company's development, where the focus shifts to stronger product commercialization. During the change negotiations, we aim to find solutions that will enable us to adapt our operations to meet this change and ensure our long-term competitiveness and profitability. Our goal is to build a strong foundation for the future," says the company's CEO, Jukka Tapaninen.

The change negotiations will start in week 45. The results of the negotiations will be announced upon their conclusion. Any potential measures will be implemented by the end of 2025.

Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/

 

Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

 

About Aiforia 

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com